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White‑tailed deer S96 prion protein 
does not support stable in vitro 
propagation of most common CWD 
strains
Alicia Otero1,2, Camilo Duque Velásquez1,2, Judd Aiken2,3 & Debbie McKenzie1,2*
PrPC variation at residue 96 (G/S) plays an important role in the epidemiology of chronic wasting 
disease (CWD) in exposed white‑tailed deer populations. In vivo studies have demonstrated the 
protective effect of serine at codon 96, which hinders the propagation of common CWD strains 
when expressed in homozygosis and increases the survival period of S96/wt heterozygous deer after 
challenge with CWD. Previous in vitro studies of the transmission barrier suggested that following 
a single amplification step, wt and S96  PrPC were equally susceptible to misfolding when seeded 
with various CWD prions. When we performed serial prion amplification in vitro using S96‑PrPC, we 
observed a reduction in the efficiency of propagation with the Wisc‑1 or CWD2 strains, suggesting 
these strains cannot stably template their conformations on this  PrPC once the primary sequence has 
changed after the first round of replication. Our data shows the S96‑PrPC polymorphism is detrimental 
to prion conversion of some CWD strains. These data suggests that deer homozygous for S96‑PrPC 
may not sustain prion transmission as compared to a deer expressing G96‑PrPC.
Chronic wasting disease (CWD) is a prion disease affecting multiple species of cervids in North America, South 
Korea, and Scandinavia. Prion diseases, which also include scrapie in sheep and goats, bovine spongiform 
encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans, are fatal diseases produced by the 
aberrant misfolding of the cellular prion protein  (PrPC) into an infectious isoform  (PrPCWD) which accumulates 
in the brain causing  neurodegeneration1.  PrPCWD is resistant to protease K (PK) digestion producing a resistant 
core referred to as  PrPRes [reviewed  by2].  PrPC is encoded in all mammalian species by the PRNP gene and is 
expressed in numerous organs with the highest levels found in the central nervous system (CNS)3. Unlike most 
prion diseases, CWD is highly contagious among farmed and wild animals, spreading through animal-to-animal 
interactions and exposure to contaminated  environments4–7.
The primary sequence of the prion protein is one of the main determinants of the susceptibility to prion 
diseases in numerous species, including humans, mice, sheep, goats and cervids. In sheep, the susceptibility to 
classical scrapie is largely regulated by amino acid variations (polymorphisms) at positions 136, 154 and 171 of the 
prion protein. The expression of alanine (A), arginine (R), arginine (R) at these positions provides great resistance 
to the  disease8–11. Accordingly, breeding programs aimed at eliminating animals expressing susceptible alleles 
and increasing the frequency of animals expressing the A136/R154/R171 haplotype have been implemented in 
sheep herds from countries where scrapie is endemic. This selective breeding for resistance has resulted in a 
significant decrease in scrapie prevalence, reducing it to almost zero in some  cases12–14. A similar approach has 
been proposed to control and/or eradicate classical scrapie in goat populations. This breeding program, although 
not yet implemented, is based on the selection of animals expressing the K222 PRNP allele, which provides a 
level of resistance to scrapie equivalent to ARR in  sheep15–18.
In cervids, there is also a close relationship between polymorphisms of the PRNP gene and CWD infec-
tion status. Supplementary Figure 1 shows sequence alignment of  PrPC polymorphisms in cervids commonly 
affected by CWD. The most common PRNP allele found in white-tailed deer populations affected by CWD 
encodes  PrPC molecules with glutamine (Q), glycine (G), alanine (A) and glutamine (Q) at positions 95, 96, 116 
and 226, respectively, and is designated as the wild-type (wt)19–25. Epidemiological studies in CWD endemic 
areas have shown that white-tailed deer expressing certain amino acid variations such as S96, H95, and G116 
OPEN
1Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada. 2Centre for Prions and Protein 
Folding Diseases, University of Alberta, Edmonton, AB, Canada. 3Department of Agricultural, Food and Nutritional 
Sciences, University of Alberta, Edmonton, AB, Canada. *email: debbie.mckenzie@ualberta.ca
2
Vol:.(1234567890)
Scientific Reports |        (2021) 11:11193  | https://doi.org/10.1038/s41598-021-90606-8
www.nature.com/scientificreports/
are underrepresented among CWD positive animals suggesting a protective effect against the  disease26–30. The 
protective effect of S96 and H95 alleles was further demonstrated by experimental oral infection in white-tailed 
deer expressing these amino acid  substitutions19. Among the alleles of the PRNP gene associated with a lower 
CWD incidence and extended preclinical phase, S96 has the highest allelic frequency (~ 25%) after the wt allele 
in several white-tailed deer populations from the United States and  Canada26,27,31. Subsequent independent 
transmission and epidemiological studies have demonstrated that deer homozygous and heterozygous for S96-
PrPC are, compared to wt/wt deer, less susceptible to CWD infection, present prolonged survival times, show 
delayed prion accumulation and are generally at a significantly earlier stage of disease when deer herds are 
 depopulated23,31–33.
Intracerebral challenge of mice expressing S96-PrPC with numerous CWD isolates has resulted in no 
 disease21,22 or incomplete attack  rates34, corroborating the impact of this polymorphism on CWD infection. The 
same S96 (tg60) mouse line is, however, susceptible to the challenge with the CWD strain  H95+, which originated 
from the passage of Wisc-1 CWD prions from wt/wt deer into deer expressing H95-PrPC25. Natural infection 
of white-tailed deer expressing G116-PrPC also resulted in different  strains35. These polymorphisms have been 
reported at relatively lower frequencies in wild and captive deer  populations27,28,30,31. By contrast, the S96-PrPC 
allele could become dominant in white-tailed deer populations exposed to CWD within a short time  frame36.
Here, we compared the efficiency with which different CWD strains induce and maintain the in vitro mis-
folding of white-tailed deer G96- and S96-PrPC molecules. Previously, cell-free conversion assays showed that 
S96-PrPC can be converted into  PrPCWD as efficiently as wt-PrPC when incubated with CWD seeds from different 
cervid  species37. Similarly, we observed that deer wt-PrPC and S96-PrPC are converted by different CWD strains 
with similar efficiencies after one round of PMCA. However, while all these CWD strains self-propagate efficiently 
in the wt-PrPC, they could not sustain serial propagation in the S96-PrPC substrate. These results suggest that 
the most common CWD strains cannot stably template their conformation on S96-PrPC, leading to the extinc-
tion of prion conversion after a few rounds of in vitro amplification in this substrate. These results reinforce the 
importance of the S96 allele as a candidate for selective breeding programs aimed at controlling and eradicating 
CWD in wild and farmed white-tailed deer populations.
Results
CWD strains replicate with similar efficiencies in a single round of PMCA with wild type and 
S96‑PrPC. Traditionally, the method for quantitatively estimating the infectivity of a prion isolate is end-point 
dilution titration in animals, generally transgenic mice expressing the prion protein of interest. This method is, 
however, time-consuming, and expensive. Therefore, numerous studies have relied on protein misfolding cyclic 
amplification (PMCA) to estimate prion infectivity in vitro. PMCA allows precise titration of prion agents in a 
few days significantly reducing the number of animals  required38–41.
We used PMCA to estimate the infectivity of different CWD strains by determining their limiting dilution 
(i.e., the highest dilution capable of producing detectable prion amplification) in brain substrates prepared 
from tg33 and tg60 mice. Tg33 mice express deer wt-PrPC (i.e., G96-PrPC) at levels ~ onefold compared to deer 
brain, whereas the  PrPC expression level in tg60 mouse brain is about 30% lower than in  tg3321,22. Therefore, to 
obtain more comparable results, we adjusted the  PrPC content of the tg33 substrates by diluting the tg33 brain 
homogenate in brain homogenate from Prnp0/0 mice.
To compare the propagation efficiency of different CWD strains in wt and S96-PrPC, 10% (wt/vol) brain 
homogenates from cervids infected with Wisc-1,  H95+25 or  CWD242 strains, and a brain homogenate from a 
mule deer naturally infected with CWD (MD inoculum) were used to prepare serial tenfold dilutions.
The Wisc-1 and  H95+ strains were obtained from two experimentally inoculated white-tailed deer, one wt 
(Q95G96) homozygous and another expressing different H95/S96  PrPC molecules,  respectively19,25. The specific 
 PrPCWD conformations of these two strains have been linked to differences in host range and reproducible neu-
ropathological, biochemical and biophysical signatures upon serial transmission into experimental  hosts24,25,43. 
The CWD2 strain was obtained from orally inoculated elk of the MM132  genotype44 and it was classified as a dif-
ferent strain based on incubation periods and histopathological features in transgenic  mice42. The MD inoculum 
was obtained from a naturally infected free ranging wt/wt mule deer from Alberta, Canada and was included for 
comparison with the Wisc-1 given the similarity in  PrPC primary sequence and  PrPRes. Bioassay characterization 
of this MD isolate is ongoing in tg33 and tg60 mice.
Aliquots from each dilution were used to seed the wt or S96 substrates. After a single round of 24 h of PMCA, 
reactions were analyzed for  PrPCWD amplification. Following one round of PMCA, both Wisc-1 and  H95+ prions 
were detectable up to the  10−5 dilution in the wt substrate and up to the  10−4 dilution in the S96 substrate (Fig. 1). 
Elk CWD2 prions propagated with the same efficiency  (10−4 dilution) in both substrates. MD CWD only propa-
gated in the wt substrate and only up to the  10−3 dilution, suggesting that white-tailed deer prions propagate more 
efficiently in both substrates. Alternatively, the Wisc-1 prions have higher seeding activity because they were 
obtained from a terminally ill experimental animal while the MD isolate was from a hunter-harvested deer sub-
mitted for CWD surveillance. Interestingly, when compared by western blot, the MD isolate had approximately 
twice the  PrPRes content compared to the Wisc-1 (not shown). Our results suggest that different CWD isolates 
propagate with similar efficiencies in both wt and S96 substrates after one round of in vitro prion amplification.
Wisc‑1 and elk CWD2 attenuation through serial PMCA on S96‑PrPC. Serial PMCA is a technique 
that enables replication of the abnormal, pathological prion protein  (PrPCWD in CWD) in vitro. After one round 
of PMCA, an aliquot of the amplified sample is diluted tenfold into fresh brain homogenate substrate and sub-
jected to another round of PMCA. This process can be repeated, obtaining newly converted  PrPCWD which is able 
to induce PrP conversion with similar efficiency as brain-derived  PrPCWD45.
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Figure 1.  PMCA amplification efficiency of different CWD isolates in wild-type (wt) and S96-PrPC substrates. 
Serial dilutions  (10−3 to  10−8) of white-tailed deer CWD strains Wisc1 and  H95+, CWD2 strain from elk and a 
CWD isolate from a naturally infected mule deer (MD) were subjected to PMCA in wt-PrPC or S96-PrPC brain 
homogenate substrates (tg33 and tg60 mouse brain homogenates, respectively). PMCA products were digested 
with PK (50 µg/ml) and analyzed by western blot. Wisc-1 and  H95+ strains propagated more efficiently in the 
wt-PrPC substrate. CWD2 strain propagated with the same efficiency in both wt and S96-PrPCsubstrates. A  10-2 
and a  10-3 dilution of the CWD2 strain in brain homogenate, not subjected to PMCA, is shown as a control of 
PMCA amplification. MD CWD only propagated in the substrate expressing wt-PrPC. mAb Sha31 1:10,000.
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Wisc-1,  H95+, CWD2 and MD CWD prions were subjected to 4 rounds of PMCA, in triplicate, in wt or 
S96-PrPC brain substrates. Analysis of the last PMCA round demonstrated that all CWD isolates propagated 
efficiently in the wt-PrPC substrate, showing abundant  PrPCWD that was biochemically indistinguishable from 
the original brain-derived seed. Surprisingly, no  PrPCWD was detected in the final round of Wisc-1 and CWD2 
amplification in the S96-PrPC substrate. These results were unexpected, considering that these isolates propagated 
with similar efficiencies in wt and S96 substrates in the first round of PMCA. The MD CWD isolate was not able 
to propagate in the S96 substrate. Seeding of the S96-PrPC with the  H95+ strain, however, resulted in successful 
serial prion propagation (Fig. 2).
Poor prion propagation by PMCA could be due to low amounts of  PrPCWD present in the brain used as a 
 seed46. To evaluate the stability of the Wisc-1 and CWD2 strains after passage into transgenic mice, we used brain 
homogenate from a tg33 mouse challenged with the Wisc-1 strain and brain homogenate from a tgElk  mouse47 
inoculated with the CWD2 strain as seeds for serial propagation in the S96 substrate through 5 rounds of PMCA. 
Both animals were euthanized at the terminal stage of the disease and accumulated very similar amounts of 
 PrPCWD in the brain (Supplementary Figure 2). After one round of PMCA, tg33 Wisc-1 material amplified up to 
the  10−5 dilution when using the S96 substrate, and the tgElk CWD2 propagated up to the  10−4 dilution. When 
these PMCA products were subjected to a second round of PMCA in the S96 substrate, we observed that  PrPCWD 
amplification was reduced tenfold. After 5 rounds of PMCA, both tg33 Wisc-1 and tgElk CWD2 lost the ability 
to efficiently propagate in the S96 substrate (Fig. 3).
These results suggest that, although the most common CWD strains found in the wild (Wisc-1 = CWD1; 
CWD2) can misfold the white-tailed deer S96-PrPC, they apparently lack the ability to maintain prion propaga-
tion in this substrate, with  PrPCWD amplification disappearing after serial passages in the S96-PrPC background. 
Only the  H95+ strain was able to serially propagate in the S96-PrPC substrate corroborating the results obtained 
in vivo25.
To evaluate whether the extinction of seeding activity observed with Wisc-1 and CWD2 during serial PMCA 
in S96-PrPC substrate was related to the loss of affinity for the substrate or due to unstable propagation of 
alternative conformers competing and blocking each other, we tested for seeding activity in wt-PrPC substrates 
from tg33 mice. When the products of the  4th PMCA round of Wisc-1 and CWD2 in S96-PrPC substrate were 
seeded in tg33 wt-PrPC substrate no amplification occurred. Similarly, the products of the  5th PMCA round of 
Figure 2.  Serial PMCA amplification of Wisc-1,  H95+, CWD2 and MD CWD prions in wt and S96  PrPC 
substrates.  10−3 dilutions of the CWD brain homogenates from infected cervids were used to seed wt-PrPC 
substrate (tg33 mouse brain homogenate) or S96-PrPC brain substrate (tg60 mouse brain homogenate) and 
subjected to 4 serial rounds of PMCA. Amplification products were digested with PK (50 µg/ml) and analyzed 
by western blot. Although all CWD strains were serially propagated in the wt-PrPC substrate, only the  H95+ 
strain maintained its amplification efficiency in the S96-PrPC brain substrate through the serial rounds of 
PMCA. Wisc-1 and CWD2 strains lost their ability to misfold the S96-PrPC after serial rounds of PMCA. MD 
CWD isolate was not able to propagate in this substrate. mAb Sha31 1:10,000.
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tg33-derived Wisc-1 and tgElk-derived CWD2 in the S96 substrate did not amplify or generate protease resistant 
prion protein in tg33 wt-PrPC.
If these strains persisted during serial propagation in the S96-PrPC or if novel conformers emerged due to 
heterologous prion conversion, it is likely that these amplification products would seed wt-PrPC substrate in 
subsequent PMCA rounds since it is a more favorable substrate for these  strains24. We did not recover any  PrPCWD 
seeding activity from the  4th round and  5th round products of Wisc-1 and CWD2 in S96  PrPC following two 
rounds of PMCA in wt-PrPC substrate (tg33). This indicates that no infectivity was present after serial propaga-
tion with the S96-PrPC and that no novel conformers were generated by either Wisc-1 or CWD2 during in vitro 
conversion of S96-PrPC. None of the amplification replicates (n = 3) for the products of the  4th (deer strains) and 
 5th (mouse strains) rounds of Wisc-1 and CWD2 in S96-PrPC substrate contained seeding activity amplifiable 
in wt-PrPC, suggesting that Wisc-1 and CWD2 strains gradually lost their ability to misfold the S96-PrPC until 
replication became extinct and no  PrPCWD could be detected. These results contrast with previously reported 
in vivo data that demonstrated that brains from asymptomatic (PK-res negative) tg60 mice challenged with 
Wisc-1 strain can still infect tg33 mice albeit with very long incubation  periods24.
Figure 3.  Serial PMCA amplification of tg33 Wisc-1 and tgElk CWD2 prions in S96-PrPC substrate. Serial 
dilutions  (10−3 to  10−7) of brain homogenate from a tg33 mouse (expressing white-tailed deer wild-type PrP) 
infected with Wisc-1 CWD strain and a tgElk mouse (expressing elk PrP) infected with the CWD2 strain were 
serially propagated in the S96-PrPC brain substrate (tg60 mouse brain homogenate) for 5 rounds of PMCA. 
PMCA products were digested with PK (50 µg/ml) and analyzed by western blotting. Amplification efficiency 
of both strains was reduced in one log after two rounds of PMCA. After 5 rounds of PMCA no  PrPCWD 
amplification in the S96 substrate is detected with neither of the strains. mAb Sha31 1:10,000.
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Discussion
Numerous studies in wild and farmed white-tailed deer populations have demonstrated the importance of the 
prion protein sequence in the susceptibility to  CWD26–30,48. This evidence was complemented with experimental 
infections in deer or transgenic mice with  PrPC polymorphisms that slow disease progression and modulate the 
degree of  neuropathology19,23. One of these polymorphisms, S96-PrPC, is relatively common in white-tailed deer 
populations and has been suggested to be under selection as a response to CWD  epizootics26,27,31,36. We show 
that the Serine (S) at codon 96 leads to the collapse of prion conversion for the most common CWD strains 
(Wisc-1 and CWD2). We propose that the interlocking at the N-terminus between the invading  PrPCWD strain 
and the S96-PrPC controls efficient prion conversion, strain adaptation and disease susceptibility, considering 
that the Serine residue is in the N-terminus of the white-tailed deer PrP. Only the prion strain with the most 
unfolding-resistant N-terminal structure (i.e.,  H95+) was serially propagated on S96-PrPC24. Conversely, the 
Wisc-1  PrPCWD is less structurally  stable24. Our experiments suggest that, when encoded in S96-PrPCWD (after 
round 1), Wisc-1 and CWD2 strains are less functional than  H95+ at stably misfolding the S96-PrPC, impair-
ing proper  PrPC −  PrPCWD domain alignment, misfolding efficiency and leading to extinction of the colonizing 
prion conformers.
There is no effective vaccine or preventive treatment against CWD prions. Therefore, strategies to mitigate 
CWD have been aimed at detecting positive cervids and in some regions reducing their numbers to lower dis-
ease prevalence and potentially reduce horizontal transmission between cervids and decrease human exposure. 
Breeding programs directed at increasing the frequency of PRNP alleles associated with resistance to scrapie, 
implemented by many European countries since  200149, have been very effective for the control of the  disease14. 
These programs are based on the elimination of animals expressing the most susceptible  genotypes50 and gradual 
replacement with more resistant sheep through the introduction of breeding males of the ARR/ARR genotype.
While the ARR haplotype confers almost complete resistance to  scrapie51,52, there is no known deer PRNP 
polymorphism that prevents CWD  infection23,31. The S96 allele is, despite this, a good candidate for the genetic 
selection of deer in herds at risk of CWD exposure. After the depopulation of a CWD positive white-tailed deer 
farm in Wisconsin, it was found that 88% of the deer were positive for  PrPCWD accumulation in at least one tissue, 
and the age of the positive animals ranged from fawns to adult deer. From this cohort, only two adult deer had 
the S96/S96 PRNP genotype, with only one of them showing faint  PrPCWD accumulation in the retropharyngeal 
lymph nodes, while the other animal was negative. Further studies have demonstrated that deer expressing the 
S96 allele in homozygosity not only are less susceptible to CWD infection, but are also found in a significant 
earlier stage of the disease than deer of the wt  genotype31,33. These observations and the older age at which posi-
tive S96 deer are detected compared to wt/wt deer, indicate the serine at this codon affects prion conversion 
resulting in slow disease progression.
These conclusions are consistent with the results of experimental infections under controlled conditions in 
deer and transgenic mice expressing S96 or wt-PrPC21–25,34. In contrast, previous in vitro replication experiments 
in which  [35S]-labeled recombinant wt or S96  PrPC were exposed to different CWD prions showed that both 
prion proteins are equally susceptible to  misfolding37. While, in vivo, the conversion of S96-PrPC into PK-res 
 PrPCWD during Wisc-1 infection in tg60 mice was inefficient and resulted in low levels of protease-resistant prion 
 conformers24. These novel S96-PrPRes molecules were unable to adapt in vivo and were unstable when subjected 
to PMCA with S96-PrPC showing altered  PrPRes  glycotypes24. These results indicated that, although the Wisc-1 
strain can persistently replicate, the S96-PrPCWD products are less structurally compatible with the S96-PrPC 
limiting the adaptation in tg60 mice. Independent transmission experiments support this interpretation for other 
CWD strains, including S96/S96 deer prions, which transmitted with incomplete attack rates when inoculated 
into tg33 mice expressing wt-PrPC and failed to adapt in tg60  mice22.
In this study, we further evaluated the capacity of S96-PrPC to support the in vitro replication of different 
CWD strains (i.e., white-tailed deer Wisc-1 and  H95+ strains, elk CWD2 strain and a mule deer (wt/wt) field 
CWD isolate). We also compared the ability of S96-PrPC and wt-PrPC substrates to support serial prion propaga-
tion. After a single round of PMCA, Wisc-1,  H95+ and CWD2 strains replicated with similar efficiencies in both 
substrates, similar results to those obtained in other in vitro replication  assays37. CWD prions from a wild mule 
deer (wt/wt genotype) were unable to misfold the S96-PrPC, which may indicate lower compatibility between this 
wt/wt mule deer CWD isolate and S96-PrPC compared to Wisc-1, CWD2 and  H95+ strains perhaps indicating a 
different strain in mule deer. Contrastingly, after several rounds of PMCA, there was no detectable amplification 
in the S96-PrPC reactions seeded with Wisc-1 or CWD2 indicating that these CWD prions lost their replication 
ability when encoded on S96-PrPCWD. Serial propagation of these two strains in wt-PrPC substrate resulted in 
efficient amplification. The loss of replicative capacity in the S96-PrPC observed with these two strains (Wisc-1 
and CWD2) but not with the control  H95+ strain (propagated in parallel and in the same sonicator), is a phenom-
enon that has not been described during in vitro propagation of prions under standard serial passage conditions.
Previous transmission studies have hypothesized CWD prion strain diversification or differential strain 
amplification from natural prion strain mixtures following transmission of cervid prions into transgenic mice 
overexpressing homologous  PrPC42. To evaluate these propositions, we repeated the serial replication experiment 
with S96-PrPC, seeding this time with brain homogenates from transgenic mice that had succumbed to prion 
disease after inoculation of Wisc-1 and CWD2 from the deer and elk. Each strain was obtained by passage in 
hosts of homologous  PrPC (tg33 and tgElk lines, respectively) that were euthanized with advanced signs of prion 
disease and contained similar levels of  PrPCWD in the brain. The seeding activity in both tg33 and tgElk mice was 
approximately equivalent as estimated by limiting dilution and a single round of PMCA. Generally, the amount of 
prions in the input inocula is a major factor influencing the maximum dilution of brain homogenate detectable 
by  PMCA46. Serial PMCA amplification allows the detection of highly diluted prion agents with a sensitivity that 
could exceed that of the mouse bioassay by  104 to  105-fold40,41,53,54. Serial rounds of PMCA in principle always 
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allow the generation of large amounts of  PrPRes which is accompanied by an increase in western blot detection 
of the limiting dilutions of the original  seed54. Here, however, we observed the opposite effect with the S96 sub-
strate. The PMCA efficiency in generating  PrPRes decreased with each round for both strains only while serially 
propagated in S96-PrPC. After 5 rounds of serial PMCA, we did not detect generation of S96-PrPRes with either 
Wisc-1 or CWD2 confirming the results obtained when the inocula was from deer and elk. No emergence of 
alternate prion strain conformers (e.g.,  H95+) was observed suggesting faithful strain replication upon transfer 
of the prion strains between the brains of two host species (white-tailed deer and elk into transgenic mice) with 
the same  PrPC.
These results confirm that the white-tailed deer  Wisc-1 CWD strain, which is favorably propagated in wt-
PrP, suffered a gradual loss of replicative capacity when encoded on S96-PrPCWD indicating the residues directly 
interacting with the S96-PrPC have less affinity than Wisc-1 encoded on wt-PrPCWD. These observations made 
here reconcile the apparently conflicting results previously obtained by exposing the white-tailed deer S96-PrPC 
to prions from animals of the wt genotype in vitro and in vivo. We must also consider that in vitro systems cannot 
reproduce all the pathogenic events occurring in a living organism. Animals can degrade a significant amount 
of the inoculated  prions55,56 and certain neuroinflammatory mechanisms are neuroprotective in the early stage 
of prion  disease57. These phenomena are not present in in vitro assays, making the conversion of  PrPC generally 
easier and/or more efficient.
The Wisc-1 S96-PrPRes and CWD2 S96-PrPRes generated in vitro are unstable and not able to self-propagate 
when passed serially, leading to the extinction of prion amplification after several passages. This was confirmed 
by seeding wt-PrPC substrates with material from the last round of Wisc-1 and CWD2 PMCA in S96-PrPC. No 
amplification was obtained in the wt-PrPC, (not shown) indicating that these strains did not propagate at a low 
level in the S96-PrPC substrate.
These results suggest that the genetic selection for animals of the S96 genotype could be a simple and efficient 
strategy for the control of CWD in deer populations. These results, however, should be interpreted with caution. 
The introduction of breeding males of the ARR/ARR genotype in sheep has been efficient in controlling scrapie 
because the ARR haplotype provides a high degree of disease resistance even in heterozygous  animals58,59. ARR-
PrPC, together with other prion proteins, can interfere with prion replication in a dominant negative manner, 
impairing the misfolding of wt-PrPC when co-expressed in the same  organism60. Heterozygous wt/S96 deer are 
susceptible to CWD and show a similar  PrPCWD distribution to that of wt/wt deer at the terminal stage of the 
 disease20, although they present extended incubation  periods19. We suggest, therefore, that the beneficial effects 
of this genetic selection strategy on CWD control would begin to be detected after a certain percentage of S96 
homozygotes is reached in the deer population.
Another important factor to consider when proposing strategies for the control of CWD is the prion strain 
to which the animals would be exposed. The  H95+ strain maintains its replicative ability after multiple rounds in 
S96-PrPC substrate (Fig. 2). In vivo assays have also confirmed that hosts expressing S96-PrPC are susceptible to 
the challenge with this CWD  strain24,25. Genetic selection for the control of a prion disease would not necessar-
ily protect the animal against all the strains present. For example, sheep expressing the ARR allele are strongly 
resistant to classical scrapie, but susceptible to atypical  scrapie61–63. Deer selected for the expression of the S96 
allele would still be susceptible to the  H95+  strain19,24,25,36. It is possible, therefore, that selecting for deer of the 
S96-PrPC may initially have beneficial effects on CWD control, but this also could lead to the selection of other 
prion strains, such as  H95+, which would be able to propagate between deer of this genotype. The  H95+ strain 
has yet to be described in wild deer populations since this strain emerged following experimental transmission 
in deer expressing H95  PrPC24,25. In addition, the H95-PRNP allele has been described in low frequency in several 
CWD enzootic regions of North  America26,27,31. An increase in the allele frequencies of protective PRNP alleles 
in response to chronic CWD exposure can in turn result in better conditions for other strains to  emerge25,35,36.
In conclusion, S96 allele plays an important role in CWD resistance, possibly because most common prion 
strains (Wisc-1 and CWD2) cannot propagate stably misfolded S96-PrPC in vitro. Our data demonstrates that 
most common CWD prions do not maintain their replicative capacity when serially passaged in S96-PrPC sub-
strates in vitro, which is consistent with in vivo data for the Wisc-1  strain24. This suggests that even if a deer of 
the S96 genotype could be infected with these strains, transmission to other animals of the same genotype may 
not occur. Therefore, selective breeding is a potential strategy for controlling the spread of CWD. However, these 
strategies could favor emergence of less abundant strains with ability to propagate in more resistant genotypes.
Material and methods
CWD isolates. Wisc-1 and  H95+ isolates consisted of 10% brain homogenates (wt/vol in water) obtained 
from the brain of terminally ill, orally infected white-tailed deer (Odocoileus virginianus) expressing the wild-
type (Q95/G96) and H95/S96  PrPC,  respectively19,25. These isolates have been thoroughly characterized in trans-
genic mice, wild type mice and  hamsters25,43. There is no evidence demonstrating that Wisc-1 and the previously 
described CWD1 strain are different strains since they show identical glycosylation patterns and similar incuba-
tion periods and neuropathological features in transgenic  mice25,42.
CWD2 isolate was prepared from a pool of brains from three CWD positive elk (Cervus canadensis) of the 
MM132  genotype44 and was generously provided by Dr. Catherine Graham. This elk pool was characterized as 
CWD2 strain in previous studies using transgenic mice expressing deer  PrPC42.
Mule deer (Odocoileus hemionus) CWD (MD CWD isolate) was obtained from the obex region of a hunter-
harvested deer of the wild type PRNP genotype (animal ID 102565) and provided by Dr. Margo Pybus (Alberta 
Environment and Parks). This animal was culled in the 2017 Alberta hunting season and tested for CWD by 
Alberta Environment and Parks.  PrPCWD, as detected by western blot, was abundant in the brain material from 
this deer, showing a glycosylation profile indistinguishable from Wisc-1 strain.
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Tg33 Wisc-1 isolate consisted of a 10% brain homogenate (wt/vol in water) from a tg33 transgenic mouse that 
had developed terminal prion disease after the inoculation of deer Wisc-1 CWD (369 days post-inoculation)25. 
TgElk CWD2 seed was a 10% (wt/vol) brain homogenate from a transgenic mouse overexpressing elk  PrPC47 
euthanized at the terminal stage of prion disease (110 days post-inoculation) after the challenge with the CWD2 
elk pool.
Experimental procedures in mice were conducted in accordance with the Canadian Council on Animal Care 
Guidelines, Policies with approval from Animal Care and Use Committee: Health Sciences at the University of 
Alberta and ARRIVE guidelines.
Protein misfolding cyclic amplification of CWD isolates. PMCA was performed as described 
 previously45. PMCA was performed using brain homogenates from uninfected tg33 and tg60 mice as substrates. 
Tg33 mice express the wild-type  PrPC from white-tailed deer (G96) at levels ~ 1 × than those found in the deer 
brain. Tg60 mice express the white-tailed deer S96  PrPC, at levels ~ 0.7 × than those detected in the tg33 trans-
genic line. Both transgenic lines have the same strain  background21,22. After euthanasia by isoflurane inhalation, 
tg33 and tg60 mice were perfused using ice-cold PBS + 5 mM EDTA. Perfused brains were immediately frozen 
at − 80 ºC. Brain substrate (10% w/v brain homogenate) was prepared using a tissue grinder, and the brains were 
homogenized in PMCA conversion buffer (PBS + 150 mM NaCl, 1% Triton X-100 + 0.5 M EDTA, 1 × Protease 
Inhibitor Cocktail). Aliquots of 90 µl were prepared with brain homogenates from tg60 mice and stored at − 80 
ºC. Since tg60 mice express 30% less  PrPC than tg33 mice, tg33 substrates were diluted with a perfused brain 
homogenate from Prnp0/0 mice, obtaining substrates with an equivalent  PrPC amount.
For the titration of the CWD agents, CWD seeds were diluted from  102 to  107 -fold in conversion buffer. Then, 
10 µl of each dilution were used to seed 90 µl of tg33 or tg60 substrate. Three PTFE beads (3/32″; McMaster-
Carr) were added to each PMCA reaction to increase the efficiency of prion  amplification39. Seeded substrates 
were placed on the plate holder of a S-4000 Misonix sonicator (QSonica, Newtown, CT, USA) and subjected to 
one round of PMCA consisting of incubation cycles of 15 min at 37 ºC without shaking, followed by sonication 
pulses of 30 s at 60% power. After a round of 24 h of PMCA, samples were analyzed for  PrPCWD amplification.
Analysis of serial amplification of Wisc-1, CWD2,  H95+ and MD deer CWD isolates in wt or S96-PrPC was 
performed by diluting the CWD seeds  103-fold into 10% normal tg33 or tg60 brain homogenates. Each of these 
reactions was seeded in triplicate and carried out in the same sonicator, using identical PMCA conditions. Reac-
tions were subjected to PMCA for 24 h. After this first round, 10 µl of the PMCA products were diluted into 
90 µl of fresh substrate and sonicated again, repeating this process through 4 rounds of PMCA. Tg33 Wisc-1 
and tgElk CWD2 seeds were serially diluted  (10−3 to  10−7) in the tg60 substrate and propagated for 5 rounds of 
PMCA. Both serial PMCA experiments were performed twice obtaining the same results.
Biochemical analysis of PMCA products. PMCA amplified samples were protease digested using 50 µg/
ml PK during 1  h at 37 ºC with constant agitation (700  rpm). Digestion was terminated by the addition of 
2 × Laemmli sample buffer (150 mM Tris–HCl, pH 6.8, 0.5% bromophenol blue, 25% glycerol, 5% [wt/vol] SDS, 
12.5% ß-mercaptoethanol) and boiling at 100 ºC for 10 min. Samples were analyzed by western blot. Immuno-
detection of  PrPCWD was performed with mouse monoclonal antibody Sha31 (1:10,000; Cayman Chemical) and 
alkaline phosphatase-conjugated goat anti-mouse secondary antibody (1:10,000; Promega). Blots were devel-
oped using the AttoPhos AP Fluorescent Substrate System (Promega).
Data availability
Data available within the article and its supplementary materials.
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